Glenmark to conduct trials in India for potential COVID-19 drug

Glenmark Pharmaceuticals Ltd said on Thursday it will start clinical trials in India of antiviral drug favipiravir, seen as a potential treatment for COVID-19, sending its shares up as much as 9% The trials come after a Chinese official told reporters last month that an active ingredient of the drug had been effective, with no obvious side effects, in helping coronavirus patients recover.